Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS.

Several processes take place during an attack of demyelination in multiple sclerosis (MS). The timing of these various processes, and thus of the attack in its entirety, is important if therapeutic stratagies are to be planned. Attempts have been made to introduce and investigate variables relevant to timing the disease processes, leading to staging systems for MS. Here, the terminology and the various parameters used are reviewed, including inflammatory cells, glial cells, axonal loss and myelin staining; then the different systems are compared, including the system put forward by Bo and Trapp, our own modification of that, the Bruck and Lassmann system and the recent consensus reached at a Vienna meeting. It is concluded that an ideal staging system does not yet exist, and that, more than anything else, the material dictates the choice for a staging system. The terminology of the Vienna consensus could be used as a reference to facilitate international comparison.

[1]  L. Scheinberg,et al.  Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[2]  J. Cossins,et al.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions , 1997, Acta Neuropathologica.

[3]  P. Dore‐Duffy,et al.  Expression of immunologically relevant endothelial cell activation antigens on isolated central neurvous system microvessels from patients with multiple sclerosis , 1994, Annals of neurology.

[4]  W. Mcdonald,et al.  The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.

[5]  Hans Lassmann,et al.  Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.

[6]  J. Benjamins,et al.  Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[7]  Remyelination in multiple sclerosis , 1979, Annals of neurology.

[8]  H. Lassmann,et al.  Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna , 1998, Journal of Neuroimmunology.

[9]  W. Brück,et al.  Oligodendrocytes in the early course of multiple sclerosis , 1994, Annals of neurology.

[10]  U. Traugott Multiple sclerosis: relevance of Class I and Class II MHC-expressing cells to lesion development , 1987, Journal of Neuroimmunology.

[11]  R. Sobel,et al.  Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. , 1990, The American journal of pathology.

[12]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[13]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.

[14]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[15]  Jack Antel,et al.  Phenotypic Differences between Human Monocytes/Macrophages and Microglial Cells Studied In Situ and In Vitro , 1994, Journal of neuropathology and experimental neurology.

[16]  C. Brosnan,et al.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.

[17]  A. Olivier,et al.  Fc Receptors for IgG on Cultured Human Microglia Mediate Cytotoxicity and Phagocytosis of Antibody-coated Targets , 1994, Journal of neuropathology and experimental neurology.

[18]  A. Compston The 150th anniversary of the first depiction of the lesions of multiple sclerosis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[19]  P. Sminia,et al.  Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. , 1999, Journal of neuropathology and experimental neurology.

[20]  K. Jellinger,et al.  Patterns of oligodendroglia pathology in multiple sclerosis. , 1994, Brain : a journal of neurology.

[21]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[22]  R. Weller A Colour Atlas of Multiple Sclerosis and Other Myelin Disorders , 1989 .

[23]  Moses Rodriguez,et al.  Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.

[24]  J. Newcombe,et al.  Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions , 1998, Journal of Neuroimmunology.

[25]  C. Raine,et al.  Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions , 1976, Neurology.

[26]  G. D. De Meyer,et al.  RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. , 1998, The American journal of pathology.

[27]  C. Raine,et al.  Multiple sclerosis: Oligodendrocytes display cell death–related molecules in situ but do not undergo apoptosis , 1997, Annals of neurology.

[28]  M. Cuzner,et al.  Microglia Express MHC Class II in Normal and Demyelinating Human White Matter , 1988, Annals of the New York Academy of Sciences.

[29]  C. Brosnan,et al.  Cytokine localization in multiple sclerosis lesions , 1995, Neurology.

[30]  B. Trapp,et al.  Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions , 1994, Journal of Neuroimmunology.

[31]  R. Sobel,et al.  Fibronectin in multiple sclerosis lesions. , 1989, The American journal of pathology.

[32]  Hans Lassmann,et al.  Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.

[33]  M. Goebeler,et al.  The calcium‐binding proteins MRP8 and MRP14 form a membrane‐associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions , 1992, European journal of immunology.

[34]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[35]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[36]  C. Lumsden Fundamental Problems in the Pathology of Multiple Sclerosis and Allied Demyelinating Diseases* , 1951, British medical journal.